Abstract
Cefonicid (Smith Kline & French Laboratories; D-75073) is a new parenteral cephalosporin with a markedly long half-life, high serum levels, and good in vitro activity against Haemophilus influenzae. Patients with community-acquired pneumonia were randomized 2:1 to receive cefonicid, 1 g daily (21 cases) or cefamandole, 1 g every 6 h (12 cases). The two groups were similar, except that the cefonicid patients were older (mean 42 versus 31 years). Peak serum levels of cefonicid averaged 133 microgram/ml after intravenous and 83 microgram/ml after intramuscular administration compared with 55 microgram/ml with intravenous cefamandole. All 9 patients on intramuscular cefonicid and 8 or 12 patients on intravenous cefonicid had trough serum levels of greater than 2.0 microgram/ml at 24 h. Sputum levels of cefonicid were usually between 2.0 and 4.0 microgram/ml and did not correlate with serum levels. Cefonicid was well tolerated, and all cefonicid patients responded clinically. Sputum cultures for H. influenzae or Streptococcus pneumoniae became negative in 6 of 7 cefamandole patients and 13 or 15 cefonicid patients. In in vitro studies, cefonicid inhibited 90% of beta-lactamase-negative h. influenzae at 0.5 microgram/ml and beta-lactamase-positive strains at 2.0 microgram/ml. Cefonicid inhibited 50% of S. pneumoniae at 1.6 microgram/ml, but required 6.4 microgram/ml to inhibit 90%. Cefonicid once a day appears to be as safe and as effective as cefamandole four times a day for therapy of community-acquired pneumonia.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Azimi P. H., Chase P. A. The role of cefamandole in the treatment of Haemophilus influenzae infections in infants and children. J Pediatr. 1981 Jun;98(6):995–1000. doi: 10.1016/s0022-3476(81)80616-6. [DOI] [PubMed] [Google Scholar]
- Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
- Chartrand S. A., Marks M. I., Roberts R., Jubelirer D. P., Plunket D. C. Development of Haemophilus influenzae meningitis in patients treated with cefamandole. J Pediatr. 1981 Jun;98(6):1003–1005. doi: 10.1016/s0022-3476(81)80618-x. [DOI] [PubMed] [Google Scholar]
- Delgado D. G., Brau C. J., Cobbs C. G., Dismukes W. E. Clinical and laboratory evaluation of cefamandole in the therapy of Haemophilus spp. Bronchopulmonary infections. Antimicrob Agents Chemother. 1979 Jun;15(6):807–812. doi: 10.1128/aac.15.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Finch C. A., Wilkinson H. W. Practical considerations in using counterimmunoelectrophoresis to identify the principal causative agents of bacterial meningitis. J Clin Microbiol. 1979 Oct;10(4):519–524. doi: 10.1128/jcm.10.4.519-524.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Petty B. G., Smith C. R., Wade J. C., Conrad G. L., Lipsky J. J., Ellner J. J., Lietman P. S. Double-blind comparison of cefamandole and penicillin in pneumococcal pneumonia. Antimicrob Agents Chemother. 1978 Jul;14(1):13–18. doi: 10.1128/aac.14.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reimer L. G., Stratton C. W., Reller L. B. Minimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum. Antimicrob Agents Chemother. 1981 Jun;19(6):1050–1055. doi: 10.1128/aac.19.6.1050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wong G. A., Pierce T. H., Goldstein E., Hoeprich P. D. Penetration of antimicrobial agents into bronchial secretions. Am J Med. 1975 Aug;59(2):219–223. doi: 10.1016/0002-9343(75)90356-3. [DOI] [PubMed] [Google Scholar]